Skip to main content

Moderna, Inc. guidance

  • MRNA · Nasdaq
  • Biotechnology
  • S&P 500
$211.43−1.79%Close 17 Nov 2026 · Market value $82.86B

In its results release of 6 Nov 2026 (Q3 FY2026), Moderna, Inc. gave 2 forecasts in figures, among them revenue growth of +15% to +25% for FY2026.

Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.

Latest guidance given with Q3 FY2026 results, 6 Nov 2026

MeasurePeriodGuidanceAs stated
Revenue growthFY2026+15% to +25%Increases 2026 expected revenue growth to 15%-25%, exceeding the previous expectation of up to 10% growth
Capital expendituresFY2026About $200MCapital Expenditures: Capital expenditures for 2026 are expected to be approximately $0.2 billion, improved from the previous expectation of $0.2 billion to $0.3 billion.

Source: the company's earnings release.

Guidance against results last two years

The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.

MeasurePeriodLast guidanceRevisionsDeliveredResult
Revenue growthFY2026+15% to +25%Given once—To come
Capital expendituresFY2026About $200MLowered once—To come

MRNA in the terminal

Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.